Clinical Microbiology and Infection最新文献

英文中文

Revisiting diagnostics: erythrocyte sedimentation rate and C-reactive protein: it is time to stop the zombie tests. 重新审视诊断：ESR 和 CRP：是时候停止 "僵尸测试 "了。

IF 10.9 1区医学 Q1 INFECTIOUS DISEASES

Clinical Microbiology and Infection

Pub Date : 2025-01-01 Epub Date: 2024-08-28 DOI: 10.1016/j.cmi.2024.08.017

Brad Spellberg, Travis B Nielsen, Matthew C Phillips, Bassam Ghanem, Tom Boyles, Boris Jegorović, Brent Footer, Jordan K Mah, Anthony Lieu, Jake Scott, Noah Wald-Dickler, Todd C Lee, Emily G McDonald

引用次数: 0

Erratum to 'TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate' [Clin Microbiol Infect (30) (2024) 743-754]. 用于治疗成人 COVID-19 的 TMPRSS2 抑制剂：萘伐司他和甲磺酸卡莫司他随机临床试验的系统回顾和荟萃分析》的勘误[《临床微生物学与感染》30 (2024) 743-754]。

IF 10.9 1区医学 Q1 INFECTIOUS DISEASES

Clinical Microbiology and Infection

Pub Date : 2025-01-01 Epub Date: 2024-08-08 DOI: 10.1016/j.cmi.2024.08.005

María Patricia Hernández-Mitre, Susan C Morpeth, Balasubramanian Venkatesh, Thomas E Hills, Joshua Davis, Robert K Mahar, Grace McPhee, Mark Jones, James Totterdell, Steven Y C Tong, Jason A Roberts

引用次数: 0

Re: 'Nirmatrelvir/ritonavir treatment and risk for post-acute sequelae of COVID-19 infection in older Singaporeans' by Wee et al. 关于Wee等人撰写的 "Nirmatrelvir/ritonavir治疗与新加坡老年人COVID-19急性后遗症的风险"。

IF 10.9 1区医学 Q1 INFECTIOUS DISEASES

Clinical Microbiology and Infection

Pub Date : 2025-01-01 Epub Date: 2024-09-26 DOI: 10.1016/j.cmi.2024.09.022

Hinpetch Daungsupawong, Viroj Wiwanitkit

引用次数: 0

Cefiderocol-resistant hypervirulent Klebsiella pneumoniae with CirA deficiency and co-production of KPC-2 and SHV-12. 耐头孢球蛋白的高病毒性肺炎克雷伯菌病例报告，该菌缺乏 CirA，并同时产生 KPC-2 和 SHV-12。

IF 10.9 1区医学 Q1 INFECTIOUS DISEASES

Clinical Microbiology and Infection

Pub Date : 2025-01-01 Epub Date: 2024-09-07 DOI: 10.1016/j.cmi.2024.08.014

Peng Lan, Ye Lu, Weichao Liao, Yunsong Yu, Ying Fu, Jiancang Zhou

引用次数: 0

Infections in immunocompromised hosts: progress made and challenges ahead. 免疫力低下宿主的感染：取得的进展和面临的挑战。

IF 10.9 1区医学 Q1 INFECTIOUS DISEASES

Clinical Microbiology and Infection

Pub Date : 2025-01-01 Epub Date: 2024-10-22 DOI: 10.1016/j.cmi.2024.10.017

Joseph Sassine, Chrysanthi Skevaki, Roy F Chemaly

引用次数: 0

Effects of long-term corticosteroid use on susceptibility to respiratory viruses: a narrative review. 长期使用皮质类固醇对呼吸道病毒易感性的影响：叙述性综述。

IF 10.9 1区医学 Q1 INFECTIOUS DISEASES

Clinical Microbiology and Infection

Pub Date : 2025-01-01 Epub Date: 2024-09-25 DOI: 10.1016/j.cmi.2024.09.014

Paraskevi C Fragkou, Dimitra Dimopoulou, Charalampos D Moschopoulos, Chrysanthi Skevaki

Background: Synthetic glucocorticoids are among the most commonly administered drugs due to their potent immunomodulatory properties. However, they may put patients at risk for infections. Their effect on the incidence of respiratory viral infections (RVIs) remains unclear.

Objectives: The aim of this review is to provide an insightful overview of the most up-to-date evidence regarding the extent to which the use of corticosteroids (CSs) influences the risk of RVIs.

Sources: The PubMed database was searched for studies on the association between CSs and RVIs from inception until 15 December 2023.

Content: CSs have differing impacts on the risk of RVIs in asthma and chronic obstructive pulmonary disease, influenced by both the specific virus and the type and dose of CSs. Furthermore, current data demonstrate that CSs may increase the risk of RVIs in patients with systemic lupus erythematosus, rheumatoid arthritis, vasculitis, solid tumours, haematological malignancies, and among transplant recipients.

Implications: Large-scale studies are imperative to inform a more accurate and personalized risk stratification for RVIs. This, in turn, will point towards new strategies for RVI prevention and associated morbidity and mortality in high-risk populations.

背景：合成糖皮质激素具有强大的免疫调节作用，是最常用的药物之一。然而，它们可能会使患者面临感染风险。它们对呼吸道病毒感染（RVI）发病率的影响仍不清楚：本综述旨在提供有关使用皮质类固醇（CSs）在多大程度上影响 RVIs 风险的最新证据的深刻概述：资料来源：在PubMed数据库中搜索了从开始到2023年12月15日有关皮质类固醇与RVI之间关系的研究：CSs 对哮喘和慢性阻塞性肺病的 RVIs 风险具有不同的影响，这受到特定病毒以及 CSs 类型和剂量的影响。此外，目前的数据表明，CSs 可能会增加系统性红斑狼疮、类风湿性关节炎、血管炎、实体瘤、血液恶性肿瘤患者以及移植受者发生 RVIs 的风险：大规模研究势在必行，以便为更准确、更个性化的 RVI 风险分层提供信息。这反过来又将为高危人群的 RVI 预防及相关发病率和死亡率的新策略指明方向。

{"title":"Effects of long-term corticosteroid use on susceptibility to respiratory viruses: a narrative review.","authors":"Paraskevi C Fragkou, Dimitra Dimopoulou, Charalampos D Moschopoulos, Chrysanthi Skevaki","doi":"10.1016/j.cmi.2024.09.014","DOIUrl":"10.1016/j.cmi.2024.09.014","url":null,"abstract":"Background: Synthetic glucocorticoids are among the most commonly administered drugs due to their potent immunomodulatory properties. However, they may put patients at risk for infections. Their effect on the incidence of respiratory viral infections (RVIs) remains unclear.Objectives: The aim of this review is to provide an insightful overview of the most up-to-date evidence regarding the extent to which the use of corticosteroids (CSs) influences the risk of RVIs.Sources: The PubMed database was searched for studies on the association between CSs and RVIs from inception until 15 December 2023.Content: CSs have differing impacts on the risk of RVIs in asthma and chronic obstructive pulmonary disease, influenced by both the specific virus and the type and dose of CSs. Furthermore, current data demonstrate that CSs may increase the risk of RVIs in patients with systemic lupus erythematosus, rheumatoid arthritis, vasculitis, solid tumours, haematological malignancies, and among transplant recipients.Implications: Large-scale studies are imperative to inform a more accurate and personalized risk stratification for RVIs. This, in turn, will point towards new strategies for RVI prevention and associated morbidity and mortality in high-risk populations.","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":"43-48"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ESR and CRP: it is time to stop the zombie tests: author's response. ESR和CRP：是时候停止 "僵尸检验 "了》--作者回复。

IF 10.9 1区医学 Q1 INFECTIOUS DISEASES

Clinical Microbiology and Infection

Pub Date : 2025-01-01 Epub Date: 2024-10-05 DOI: 10.1016/j.cmi.2024.09.029

Brad Spellberg, Bassam Ghanem, Tom Boyles, Todd C Lee, Emily G McDonald

引用次数: 0

Candida auris MIC testing by EUCAST and clinical and laboratory standards institute broth microdilution, and gradient diffusion strips; to be or not to be amphotericin B resistant? 通过 EUCAST 和 CLSI 肉汤微量稀释及梯度扩散条进行的念珠菌 MIC 检测；对两性霉素 B 是否耐药？

IF 10.9 1区医学 Q1 INFECTIOUS DISEASES

Clinical Microbiology and Infection

Pub Date : 2025-01-01 Epub Date: 2024-10-18 DOI: 10.1016/j.cmi.2024.10.010

Maiken Cavling Arendrup, Shawn R Lockhart, Nathan Wiederhold

Objectives: Reported amphotericin B resistance rates for Candida auris vary considerably. This may reflect clinically relevant differences in susceptibility, technical issues with testing, or adoption of a clinical breakpoint that bisects the wild-type population. We compared reference methods and two gradient diffusion strips using a shared C. auris strain collection.

Methods: Forty C. auris strains from nine U.S. states and ≥3 clades were included. Fourteen MIC data sets were generated using European Committee on Antimicrobial Susceptibility Testing (EUCAST) E.Def 7.4, Clinical and Laboratory Standards Institute (CLSI) M27Ed4, Etest, and MIC gradient test strip (MTS, Liofilchem) MICs. MICs ≤1 mg/L were classified as susceptible.

Results: EUCAST and CLSI amphotericin B MIC testing were robust across the included method variables. The modal MIC was 1 mg/L, distributions unimodal and narrow with similar geometric mean (GM)-MICs (0.745-1.072); however, susceptibility classification varied (0-28% resistance). Gradient diffusion strip testing resulted in wider and bimodal distributions for 8/9 data sets. If adopting, per manufacturer's protocol, double inoculation for the Etest method, the modal MIC increased to 2-4 mg/L and resistance rates to 45-63% versus 25-30% with the single inoculation. The EUCAST, CLSI, Etest, and MTS strip MICs correlated to the optical density of drug-free control EUCAST wells, suggesting that some isolates grew better than others and that this was associated with MIC.

Discussion: The EUCAST and CLSI MIC results were in close agreement, whereas the strip test showed wider and bimodal distributions with reader to reader and centre to centre variation. Our study adds to the concern for commercial MIC testing of amphotericin B against C. auris and suggests the current breakpoint leads to random susceptibility classification.

目的：据报道，白色念珠菌对两性霉素 B 的耐药率差异很大。这可能反映了与临床相关的药敏性差异、检测技术问题或采用了将野生型群体一分为二的临床断点（BP）。我们使用共享的 C. auris 菌株库比较了参考方法和两种梯度扩散条：方法：纳入了来自美国九个州、≥3 个支系的 40 株 C. auris 菌株。使用 EUCAST E.Def 7.4、CLSI M27Ed4、Etest 和 MTS（Liofilchem）条带 MIC 生成 14 个 MIC 数据集。MIC≤1 mg/L 被归类为易感：结果：EUCAST和CLSI两性霉素B的MIC测试在各种方法变量中都很稳健。模态 MIC 为 1 毫克/升，呈单峰分布，范围较窄，GM-MIC 相似（0.745-1.072）；但药敏性分类各不相同（0-28% 抗药）。梯度扩散带测试结果显示，8/9 个数据集的分布较宽且呈双峰分布。如果按照制造商的协议，在 Etest 方法中采用双重接种，则模态 MIC 增加到 2-4 mg/L，耐药率增加到 45-63%，而单次接种的耐药率为 25-30%。EUCAST、CLSI、Etest和MTS条带的MIC与无药对照EUCAST孔的OD相关，表明一些分离物比其他分离物生长得更好，这与MIC有关：结论：EUCAST 和 CLSI 的 MIC 结果接近一致，而条带测试则显示出更广泛的双峰分布，读者与读者之间以及中心与中心之间存在差异。我们的研究增加了人们对两性霉素 B 抗球虫商业 MIC 检测的担忧，并表明目前的断点会导致随机药敏性分类。

{"title":"Candida auris MIC testing by EUCAST and clinical and laboratory standards institute broth microdilution, and gradient diffusion strips; to be or not to be amphotericin B resistant?","authors":"Maiken Cavling Arendrup, Shawn R Lockhart, Nathan Wiederhold","doi":"10.1016/j.cmi.2024.10.010","DOIUrl":"10.1016/j.cmi.2024.10.010","url":null,"abstract":"Objectives: Reported amphotericin B resistance rates for Candida auris vary considerably. This may reflect clinically relevant differences in susceptibility, technical issues with testing, or adoption of a clinical breakpoint that bisects the wild-type population. We compared reference methods and two gradient diffusion strips using a shared C. auris strain collection.Methods: Forty C. auris strains from nine U.S. states and ≥3 clades were included. Fourteen MIC data sets were generated using European Committee on Antimicrobial Susceptibility Testing (EUCAST) E.Def 7.4, Clinical and Laboratory Standards Institute (CLSI) M27Ed4, Etest, and MIC gradient test strip (MTS, Liofilchem) MICs. MICs ≤1 mg/L were classified as susceptible.Results: EUCAST and CLSI amphotericin B MIC testing were robust across the included method variables. The modal MIC was 1 mg/L, distributions unimodal and narrow with similar geometric mean (GM)-MICs (0.745-1.072); however, susceptibility classification varied (0-28% resistance). Gradient diffusion strip testing resulted in wider and bimodal distributions for 8/9 data sets. If adopting, per manufacturer's protocol, double inoculation for the Etest method, the modal MIC increased to 2-4 mg/L and resistance rates to 45-63% versus 25-30% with the single inoculation. The EUCAST, CLSI, Etest, and MTS strip MICs correlated to the optical density of drug-free control EUCAST wells, suggesting that some isolates grew better than others and that this was associated with MIC.Discussion: The EUCAST and CLSI MIC results were in close agreement, whereas the strip test showed wider and bimodal distributions with reader to reader and centre to centre variation. Our study adds to the concern for commercial MIC testing of amphotericin B against C. auris and suggests the current breakpoint leads to random susceptibility classification.","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":"108-112"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Should multiplex PCR testing be integrated into antimicrobial stewardship programs for paediatric community-acquired pneumonia in the emergency department? 多重 PCR 检测是否应纳入急诊科儿科社区获得性肺炎抗菌药物管理计划？

IF 10.9 1区医学 Q1 INFECTIOUS DISEASES

Clinical Microbiology and Infection

Pub Date : 2025-01-01 Epub Date: 2024-08-28 DOI: 10.1016/j.cmi.2024.08.028

Paul Loubet, Slim Fourati, Donia Bouzid

引用次数: 0

Which trial do we need? Combination therapy with daptomycin plus ceftaroline versus standard-of-care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteraemia. 我们需要哪种试验？在治疗耐甲氧西林金黄色葡萄球菌菌血症时，达托霉素加头孢他啶联合疗法与标准单一疗法的对比。

IF 10.9 1区医学 Q1 INFECTIOUS DISEASES

Clinical Microbiology and Infection

Pub Date : 2025-01-01 Epub Date: 2024-09-07 DOI: 10.1016/j.cmi.2024.08.011

Myeongji Kim, Nischal Ranganath, Supavit Chesdachai, Ryan W Stevens, Muhammad Rizwan Sohail, Omar M Abu Saleh

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Clinical Microbiology and Infection

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀